AIMSTM enables an innovative biomarker led drug pipeline
Focusing on emerging drug targets, Protai's AIMSTM platform paves the way to a unique precision medicine approach, facilitating an accelerated drug development process
PRT-002 (KAT6A)
Small molecule
PROTAC
PRT-003 (I&I)
PRT-004 (I&I)
PRT-005 (Oncology)
Multiple PPI assets
STAGE
Discovery
Lead optimization
IND Enabling
Collaborate with us
Our portfolio and pipeline assets extend from early discovery through to late preclinical and we are looking to engage with pharma companies with potential interest in partnering/licensing our assets.
